Literature DB >> 7173273

Species differences in phenazepam kinetics and metabolism.

V P Zherdev, S Caccia, S Garattini, A L Ekonomov.   

Abstract

The kinetic profiles of phenazepam and its hydroxylated derivative were compared in rat, dog, cat and man after administration of single oral doses of the parent compound. The absorption of phenazepam was reasonably rapid in all the species studied. Blood peak concentrations (Cmax) were reached at 1 h in rats (0.32 +/- 0.03 microgram/ml), at 0.5 h in dogs 0.54 +/- 0.10 microgram/ml), at about 2 h in cats (1.65 +/- 0.23 microgram/ml), about only at 4 h in man (0.038 microgram/ml) at the highest dose tested. The largest normalized (value/dose) Cmax and area under the curve (AUC) were observed in man, while the rat gave the lowest values. The half-life of phenazepam was about 60 h in man, 13.72 +/- 2.09 h in the cat, 6.35 +/- 2.32 h in the dog and 7.49 +/- 1.88 h in the rat (beta-half-life). 3-OH-phenazepam was rapidly detected in cat, rat, and dog blood but no measurable amounts (less than 3 ng/ml) were found in human blood. At the oral doses tested, the ratio of the AUC for 3-OH-phenazepam to phenazepam was 0.01, 0.48, and 0.53 in the dog, rat, and cat, respectively. The half-life of the metabolite was shorter than that of the parent compound in the dog, but it was comparable in the rat and longer in the cat. The results suggest that 3-OH-phenazepam might contribute to the overall pharmacological effects of the parent compound in those species in which it accumulates in significant amounts.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7173273     DOI: 10.1007/BF03189565

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  8 in total

1.  Gas chromatographic determination of chlorodesmethyldiazepam and lorazepam in rats and mice.

Authors:  J Lanzoni; L Airoldi; F Marcucci; E Mussini
Journal:  J Chromatogr       Date:  1979-01-11

2.  Brain concentrations of lorazepam and oxazepam at equal degree of anticonvulsant activity.

Authors:  F Marcucci; E Mussini; L Airoldi; A Guaitani; S Garattini
Journal:  J Pharm Pharmacol       Date:  1972-01       Impact factor: 3.765

3.  Further studies on species difference in diazepam metabolism.

Authors:  F Marcucci; R Fanelli; E Mussini; S Garattini
Journal:  Eur J Pharmacol       Date:  1970-02       Impact factor: 4.432

4.  Species difference in diazepam metabolism and anticonvulsant effect.

Authors:  F Marcucci; A Guaitani; J Kvetina; E Mussini; S Garattini
Journal:  Eur J Pharmacol       Date:  1968-11       Impact factor: 4.432

5.  Relationship between camazepam, N-methyl-oxazepam and oxazepam brain concentrations and antileptazol effect in the rat.

Authors:  S Caccia; M Ballabio; S Garattini
Journal:  J Pharm Pharmacol       Date:  1981-03       Impact factor: 3.765

6.  Brain concentrations of clobazam and N-desmethylclobazam and antileptazol activity.

Authors:  S Caccia; G Guiso; S Garattini
Journal:  J Pharm Pharmacol       Date:  1980-04       Impact factor: 3.765

7.  7-Bromo-5-(2'-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (I), a new tranquillizing agent: metabolism in rats.

Authors:  A L Ekonomov; A P Rodionov; V P Zherdev; Y I Vikhlyaev
Journal:  Xenobiotica       Date:  1979-08       Impact factor: 1.908

8.  Species differences in clobazam metabolism and antileptazol effect.

Authors:  S Caccia; G Guiso; R Samanin; S Garattini
Journal:  J Pharm Pharmacol       Date:  1980-02       Impact factor: 3.765

  8 in total
  3 in total

1.  First reported case in the UK of acute prolonged neuropsychiatric toxicity associated with analytically confirmed recreational use of phenazepam.

Authors:  Paul I Dargan; Susannah Davies; Malgorzata Puchnarewicz; Atholl Johnston; David M Wood
Journal:  Eur J Clin Pharmacol       Date:  2012-07-29       Impact factor: 2.953

2.  Assessment of the Availability, Cost, and Motivations for Use over Time of the New Psychoactive Substances-Benzodiazepines Diclazepam, Flubromazepam, and Pyrazolam-in the UK.

Authors:  Rachelle Abouchedid; Thea Gilks; Paul I Dargan; John R H Archer; David M Wood
Journal:  J Med Toxicol       Date:  2018-04-18

Review 3.  'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports.

Authors:  Laura Orsolini; John M Corkery; Stefania Chiappini; Amira Guirguis; Alessandro Vento; Domenico De Berardis; Duccio Papanti; Fabrizio Schifano
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.